Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

lio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, ha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is designed for ... content, to analysis of athletic performance. Producing high-resolution slow-motion video , the ... to process with the naked eye. , Slow motion sequences are commonly ...
(Date:9/1/2015)... , September 2, 2015 ... auf die Forschung und Entwicklung neuartiger Therapien ... chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält vom ... dass sein neues Medikament patentiert wird. Das ... Allergien bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is now accepting ... program. LOIs are due no later than Wednesday, October ... Discovery Grants are one-year, $50,000 grants that fund high risk/high ... or treatment paradigms for adults and children with brain ... earliest stages, in the hopes that it spurs additional ...
Breaking Biology Technology:Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Board of,Directors of Shire plc (LSE: SHP) (NASDAQ: ... today that Michael Rosenblatt M.D.,will join the Board ... Dr Rosenblatt is the Dean of Tufts University ... of Medicine at Harvard,Medical School and has served ...
... April 24 /PRNewswire/ - Aegera Therapeutics Inc. is ... biotechnology and,financial executives to its Board of Directors: ... BioScience Managers Limited, and Mr. Gary,Littlejohn, Managing Director ... industry experience and networks will be,critical for Aegera ...
... Calif., April 24 NeurogesX, Inc.,(Nasdaq: NGSX ... management therapies, announced today that it is scheduled ... Morgan Stanley Global Healthcare,Unplugged Conference. Anthony DiTonno, President ... Ghiglieri, Chief Financial Officer,will be available to respond ...
Cached Biology Technology:Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 4Aegera Therapeutics welcomes two experienced executives to its board of directors 2NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference 3
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2
... air since the Industrial Revolution appears to have changed ... new analysis published this week in Nature . ... in rivers, estuaries and continental shelves suggests that collectively ... than it releases. The shift could impact global models ...
... data centers are actually more energy efficient than ... Traditionally, computers have been cooled down with mechanical ... maintenance systems associated with servers also require electricity. ... this extra electricity negatively impacts the data centers, ...
... years, cultivated silkworms have been spinning luxurious white silk ... current dyeing practices produce wastewater that contains potentially harmful ... dyeing method in which they coax already-colored fibers from ... are published in the journal ACS Sustainable Chemistry ...
Cached Biology News:Coastal sea change 2Coastal sea change 3Data centers can be cooled down in environmentally friendly, energy efficient ways 2
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Full service including gene cloning, protien expression and purification of 1 liter culture....
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Biology Products: